Wednesday, January 14, 2009
Elan May Extend Alzheimer’s Study to Gather More Data
Elan May Extend Alzheimer’s Study to Gather More Data: "Elan Corp. may spend an additional six months testing its experimental Alzheimer’s disease treatment, potentially delaying the introduction of its most-promising new product.
The drug is one of the first designed to attack the plaque that forms clumps in the brains of people with Alzheimer’s, affecting memory and movement. The company may use the time to gather more data on the safety and effectiveness of the medicine, bapineuzumab, which was linked to brain swelling in an earlier trial, said Carlos Paya, who in November became president in charge of strategy at Dublin-based Elan."
The drug is one of the first designed to attack the plaque that forms clumps in the brains of people with Alzheimer’s, affecting memory and movement. The company may use the time to gather more data on the safety and effectiveness of the medicine, bapineuzumab, which was linked to brain swelling in an earlier trial, said Carlos Paya, who in November became president in charge of strategy at Dublin-based Elan."
